Joo Hyun O1, Woo Hee Choi1, Eun Ji Han1, Eun-Kyoung Choi1, Byung Joo Chae2, Yong-Gyu Park3, Sung Hoon Kim1. 1. Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seocho-gu Banpo-dong 505, Seoul, Republic of Korea 137-701. 2. Department of Surgery, The Catholic University of Korea, Seoul, Korea. 3. Department of Biostatistics, The Catholic University of Korea, Seoul, Korea.
Abstract
PURPOSE: We evaluated whether the maximum standardized uptake values (SUVmax) of primary tumor from the initial staging by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) of patients with breast cancer could identify patients at risk for early recurrence within 2 years, particularly in comparison to the American Joint Committee on Cancer (AJCC) stage. METHODS: We reviewed the staging (18)F-FDG PET/CT images of patients with primary breast cancer and their medical records. The SUVmax of the primary tumor was measured. The presence or absence of FDG uptake in the axillary lymph node (ALN) was also assessed. The patient's pathologic primary tumor stage (pT), pathologic regional lymph node stage (pN), stage grouping, age, estrogen receptor (ER) and progesterone receptor (PR) status, and neoadjuvant chemotherapy history were evaluated with the FDG uptake parameters for recurrence within 2 years following the end of first-line therapy. RESULTS: Recurrence within 2 years was present in 9.1 % (n = 40) out of the 441 patients assessed. The FDG uptake in ALN, pT, pN, stage grouping and neoadjuvant chemotherapy history were prognostic for early recurrence, while primary tumor SUVmax, age, and ER or PR status were not significant on logistic regression. On multivariate analysis, only the stage grouping (odds ratio 2.79; 95 % CI 1.73, 4.48; p < 0.0001) and neoadjuvant chemotherapy history (odds ratio 2.70; 95 % CI 1.22, 5.98; p = 0.0141) could identify patients at increased risk for recurrence within 2 years. CONCLUSIONS: Primary tumor FDG uptake measured by SUVmax, and visual assessment of FDG uptake in the ALN in the initial staging PET/CT of patients with breast cancer may not have additional prognostic value compared with the AJCC stage grouping for early recurrence.
PURPOSE: We evaluated whether the maximum standardized uptake values (SUVmax) of primary tumor from the initial staging by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) of patients with breast cancer could identify patients at risk for early recurrence within 2 years, particularly in comparison to the American Joint Committee on Cancer (AJCC) stage. METHODS: We reviewed the staging (18)F-FDG PET/CT images of patients with primary breast cancer and their medical records. The SUVmax of the primary tumor was measured. The presence or absence of FDG uptake in the axillary lymph node (ALN) was also assessed. The patient's pathologic primary tumor stage (pT), pathologic regional lymph node stage (pN), stage grouping, age, estrogen receptor (ER) and progesterone receptor (PR) status, and neoadjuvant chemotherapy history were evaluated with the FDG uptake parameters for recurrence within 2 years following the end of first-line therapy. RESULTS: Recurrence within 2 years was present in 9.1 % (n = 40) out of the 441 patients assessed. The FDG uptake in ALN, pT, pN, stage grouping and neoadjuvant chemotherapy history were prognostic for early recurrence, while primary tumor SUVmax, age, and ER or PR status were not significant on logistic regression. On multivariate analysis, only the stage grouping (odds ratio 2.79; 95 % CI 1.73, 4.48; p < 0.0001) and neoadjuvant chemotherapy history (odds ratio 2.70; 95 % CI 1.22, 5.98; p = 0.0141) could identify patients at increased risk for recurrence within 2 years. CONCLUSIONS:Primary tumorFDG uptake measured by SUVmax, and visual assessment of FDG uptake in the ALN in the initial staging PET/CT of patients with breast cancer may not have additional prognostic value compared with the AJCC stage grouping for early recurrence.
Entities:
Keywords:
18F-FDG PET/CT; Breast cancer; Prognosis; Staging
Authors: Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: M Oshida; K Uno; M Suzuki; T Nagashima; H Hashimoto; H Yagata; T Shishikura; K Imazeki; N Nakajima Journal: Cancer Date: 1998-06-01 Impact factor: 6.860
Authors: Ana María García Vicente; Ángel Soriano Castrejón; Jesús Fernando López-Fidalgo; Mariano Amo-Salas; María Del Mar Muñoz Sanchez; Ruth Álvarez Cabellos; Ruth Espinosa Aunión Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-09 Impact factor: 9.236